INVENTIVA (EPA:IVA) | Finanzwire

PRESS RELEASE

published on 05/05/2025 at 08:30, 8 months 25 days ago

Inventiva secures the €116 million second tranche of its structured financing of up to €348 million
BRIEF

published on 04/24/2025 at 22:06, 9 months 5 days ago

Inventiva Unveils New Biomarker Analysis for MASH Treatment

Lanifibranor MASH Treatment Biomarker Signatures Histological Response Predictive Accuracy
PRESS RELEASE

published on 04/24/2025 at 22:01, 9 months 5 days ago

Inventiva announces the publication in Clinical Gastroenterology and Hepatology of its analysis of new biomarker signatures predictive of histological response in patients with MASH treated with lanifibranor
Inventiva announces publication in Clinical Gastroenterology and Hepatology of non-invasive biomarker signatures predictive of histological response in MASH patients treated with lanifibranor

Inventiva Lanifibranor Biomarker Signatures Histological Response Clinical Gastroenterology
BRIEF

published on 04/15/2025 at 22:05, 9 months 14 days ago

Inventiva Files 2024 Financial Documents with Regulatory Agencies

Biopharmaceutical Regulatory Filing Inventiva MASH 2024 Financials
PRESS RELEASE

published on 04/15/2025 at 22:00, 9 months 14 days ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva files its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F with the AMF and SEC. Documents accessible on Inventiva's website and regulatory authorities' sites

2024 Form 20-F Registration Document Clinical-Stage Biopharmaceutical Inventiva
BRIEF

published on 03/26/2025 at 21:05, 10 months 3 days ago

Inventiva unveils its 2024 financial results and strategic projects

Strategic Reorganization 2024 Financial Results Research & Development Lanifibranor Structured Financing
PRESS RELEASE

published on 03/26/2025 at 21:00, 10 months 3 days ago

Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented

Revenues Financial Results Inventiva Cash Equivalents NATiV3 Phase 3 Trial
BRIEF

published on 03/19/2025 at 21:05, 10 months 10 days ago

Inventiva Announces 2024 Full-Year Financial Results Schedule

Financial Results Webcast Inventiva Lanifibranor MASH Treatment
PRESS RELEASE

published on 03/19/2025 at 21:00, 10 months 10 days ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva schedules 2024 Full-Year Financial Results presentation on March 27, 2025. Webcast available. Company focused on small molecule therapies for MASH

Presentation 2024 Financial Results Inventiva MASH Small Molecule Therapies
BRIEF

published on 02/26/2025 at 22:05, 11 months 3 days ago

Inventiva's Lanifibranor Shows Promise in Portal Hypertension Study

Preclinical Study Inventiva Liver Disease Lanifibranor Portal Hypertension

Published on 01/30/2026 at 14:00, 2 hours 3 minutes ago

CCL to Hold Live Webcast to Discuss Fourth Quarter and Year End 2025 Results, Thursday, February 26, 2026, at 7:30 a.m. ET
Published on 01/30/2026 at 08:35, 7 hours 28 minutes ago

Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 8 hours 3 minutes ago

Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 13 hours 48 minutes ago

Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 16 hours 3 minutes ago

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

View all ACCESSWIRE

Published on 01/30/2026 at 15:58, 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Glencore plc
Published on 01/30/2026 at 15:57, 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 01/30/2026 at 15:56, 6 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc
Published on 01/30/2026 at 15:55, 7 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 01/30/2026 at 15:55, 8 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc

View all EQS

Published on 01/30/2026 at 08:00, 8 hours 3 minutes ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 22 hours 3 minutes ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 22 hours 18 minutes ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 22 hours 18 minutes ago

Cegedim generated LFL revenue growth of 1.1% in 2025
Published on 01/29/2026 at 17:40, 22 hours 23 minutes ago

ALTEN: Annual revenue 2025

View all LES ECHOS COMFI WIRE

News